SEARCH BY NAME

BROWSE

Browse Australian delisted companies

0-9A BC DE F GH IJ KL MN OP QR ST UV WX YZ

Browse terminated Australian managed funds

0-9A BC DE FGH IJ KL MN OP QR ST UV WX YZ

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

PSIVIDA CORP. (PVA)

Delisted from ASX 07/05/2018

SHARE PRICES

Former (or subsequent) names

 

Shareholder links

Our website ranking of PVA: rating 4
(4 out of 5)
COMPANY WEBSITE:

 

REGISTRY:
Computershare, Level 2, 45 St Georges Terrace, Perth WA 6000
Tel : +61 8 9323 2000 or 1300 557 010
Fax : +61 8 9323 2033
RegistryWebsite RegistryEmail

Company details

Address: c/- Blake Dawson, Level 37, 101 Collins Street, MELBOURNE, VIC, AUSTRALIA, 3000
Tel:  (08) 9227 8327 Fax: (08) 9227 6838

Date first listed: 12/06/2008
Company Secretary: Ms Lori Freedman
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: The Company is the successor entity to pSivida Limited (ASX code: PSD), an ASX listed pharmaceutical and biotechnology development company which undertook a restructure by way of scheme of arrangement resulting in it becoming a wholly owned subsidiary of
delisted from the close of trading on Monday, 07 May 2018 pursuant to Listing rule 17.11.07/05/2018
we understand the company delisted because of a significant decrease in the proportion of the Company's Common Stock held by CDI holders, poor liquidity on the ASX, spending of about AUD100,000 a year on maintaining its listing on the ASX as a result of both direct and indirect costs and further fundraising will be more likely to be successful if the Company is not listed on the ASX (the company now called EyePoint Pharmaceuticals, Inc. trades on Nasdaq as "EYPT")07/05/2018
The securities of EyePoint Pharmaceuticals, Inc (formally pSivida Corp) will be suspended from quotation immediately under Listing Rule 17.2, at the request of the Company pursuant to the announcement dated 4 April 2018, pending delisting of the Company from the official list at the close of trade on Monday, 7 May 2018. 30/04/2018
The suspension of trading in the securities of EyePoint Pharmaceuticals, Inc (formally pSivida Corp) will be lifted immediately, following the release of the Company's response to an ASX price and volume query. 26/04/2018
The company issues a response to ASX Price and Volume Query.26/04/2018
The securities of EyePoint Pharmaceuticals, Inc (formally pSivida Corp) will be suspended from quotation immediately, in accordance with Listing Rule 17.3. The securities will remain suspended until ASX receives a response to its price and volume query.26/04/2018
the Company has changed its name to EyePoint Pharmaceuticals, Inc. and, as part of the name change, the Company's ticker symbol on the Nasdaq Global Market ("NASDAQ") has been changed from "PSDV" to "EYPT" effective on and from 2 April 2018. Trading of shares of the Company's common stock ("Common Stock") on the NASDAQ will be unaffected by the name and ticker symbol changes and will continue during and after the ASX delisting process. The Company's ASX ticker symbol, PVA, will remain unchanged29/03/2018
listed entity carried for record purposes only - we understand that shareholders in pSivida Limited received one CDI in pSivida Corp for every 40 shares they held12/06/2008

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNATURENUMBERPRICEAMOUNT
    01/10/2012Paul HopperOn market CDI10,000$1.615$16,150

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    David MazzoNon Exec Chairman25/07/2005
    Laurence FreedmanVice President, General Counsel23/05/2006
    Len RossFinance Director19/11/2009
    Douglas GodshallDirector07/03/2012
    James BarryDirector10/09/2014
    Nancy LurkerDirector, CEO16/09/2016
    Jay DukerDirector28/09/2016
    Kristine PetersonDirector27/06/2017
    Michael RogersDirector27/07/2005
    Brian LeedmanInvestor Relations
    Charles BairdLocal Agent

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Paul AshtonManaging Director, CEO30/12/200516/09/2016
    Peter SavasDirector14/07/200805/02/2016
    Paul HopperDirector09/07/200817/01/2014

    Date of first appointment, title may have changed.